BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 15453116)

  • 21. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
    Drew R
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antifungal drugs.
    Treat Guidel Med Lett; 2008 Jan; 6(65):1-8. PubMed ID: 18157085
    [No Abstract]   [Full Text] [Related]  

  • 23. Amphotericin B lipid preparations: what are the differences?
    Adler-Moore JP; Proffitt RT
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role for polyenes in treating invasive mycoses?
    Cornely OA; Vehreschild JJ; Ullmann AJ
    Curr Opin Infect Dis; 2006 Dec; 19(6):565-70. PubMed ID: 17075332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment options for invasive fungal infections.
    Dodds Ashley ES
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):55S-60S. PubMed ID: 16716123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amphotericin B use in children: conventional and lipid-based formulations.
    Kuyucu N
    Expert Rev Anti Infect Ther; 2011 Mar; 9(3):357-67. PubMed ID: 21417875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of non-conventional amphotericin B at the San Carlos Clinical Hospital].
    Prieto Yerro C; Vargas Castrillón E; Laredo Velasco L; Pérez-Cecilia E; Ambit Avila MI; Picazo de la Garza JJ
    Rev Esp Salud Publica; 2000; 74(4):351-9. PubMed ID: 11031843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antimycotic therapy].
    Schaffner A
    Ther Umsch; 1990 Aug; 47(8):664-9. PubMed ID: 2218968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid amphotericin B formulations as comparators in clinical trials.
    Powers JH; Albrecht R
    Clin Infect Dis; 2004 Jan; 38(2):305-6; author reply 306-7. PubMed ID: 14699471
    [No Abstract]   [Full Text] [Related]  

  • 33. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice?
    Turkova A; Roilides E; Sharland M
    Curr Opin Infect Dis; 2011 Apr; 24(2):163-71. PubMed ID: 21301335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antifungal drugs.
    Treat Guidel Med Lett; 2005 Feb; 3(30):7-14. PubMed ID: 15671963
    [No Abstract]   [Full Text] [Related]  

  • 38. Nephrotoxicity in the setting of invasive fungal diseases.
    Ullmann AJ
    Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amphotericin B and coccidioidomycosis.
    Johnson RH; Einstein HE
    Ann N Y Acad Sci; 2007 Sep; 1111():434-41. PubMed ID: 17513463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid formulations of amphotericins: are you a lumper or a splitter?
    Wingard JR
    Clin Infect Dis; 2002 Oct; 35(7):891-5. PubMed ID: 12228829
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.